Sharing R&D Risk in Healthcare via FDA Hedges
The Review of Corporate Finance Studies · 17.10.2022 · 11 (4) · 880-922
DOI: 10.1093/rcfs/cfab024 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Review of Corporate Finance Studies, online erschienen am 15.11.2021. Verfasst von Adam Jørring und 4 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Biomedical innovation suffers from a “funding gap” between the needs of drug development firms and the availability of funds. The requirement of large investments for drug development projects and the high pipeline risk associated with FDA approval causes this funding gap in part. In this paper, we propose a new financial instrument—the “FDA hedge”—that pays off upon FDA approval failure. We develop a theory to show that the FDA hedge can help eliminate the funding gap. Using novel project-level data, we establish empirically that FDA hedge risk is idiosyncratic, and show how better sharing this risk can spur welfare-enhancing R&D. (JEL G11, G13, G22, I11, L65, O32 Authors have furnished an Internet Appendix, which is available on the Oxford University Press Web site next to the link to the final published paper online.
Zitieren
APA
Jørring, A., Lo, A. W., Philipson, T. J., Singh, M., & Thakor, R. T. (2022). Sharing R&D Risk in Healthcare via FDA Hedges. The Review of Corporate Finance Studies, 11(4), 880-922. https://doi.org/10.1093/rcfs/cfab024
Vancouver
Jørring A, Lo AW, Philipson TJ, Singh M, Thakor RT. Sharing R&D Risk in Healthcare via FDA Hedges. The Review of Corporate Finance Studies. 2022;11(4):880-922. doi:10.1093/rcfs/cfab024
BibTeX
@article{Jrring2022,
author = {Jørring, Adam and Lo, Andrew W and Philipson, Tomas J and Singh, Manita and Thakor, Richard T},
title = {Sharing R&D Risk in Healthcare via FDA Hedges},
journal = {The Review of Corporate Finance Studies},
year = {2022},
volume = {11},
number = {4},
pages = {880--922},
doi = {10.1093/rcfs/cfab024}
}
EUVIMED